Renal cell carcinoma (RCC):
An amazing story of improved outcomes
Cora Sternberg, MD, FACP
San Camillo-Forlanini Hospital
Rome, Italy

Building on a solid base of targets and targeted agents in RCC
Bernard Escudier, MD (Chair)
Institut Gustave Roussy
Paris, France

Dealing with unmet needs in RCC in the
new era of targeted therapy
Peter Mulders, MD, PhD
Radbound University Nijmegen
Medical Centre
The Netherlands

Promising developments for castration-refractory prostate cancer (CRPC)
Johann Sebastian de Bono, MD, FRCP, MSc, PhD
Royal Marsden Hospital
London, United Kingdom